EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
What is the ‘know-how gap’ problem and how might it impact scaling up production...
This entire article is also available as a PDF by clicking here.
1. Introduction.
How relevant are concerns about intellectual property rights causing problems for...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
UN High-Level Panel on Access to Medicines calls for stronger public leadership in innovation...
The UN High-Level Panel on Access to Medicines published its report on 14 September. The Panel was established on 19 November 2015 by UN...
Vaccine knowledge needs to be a global public good: Remarks to the World Trade...
Ellen ‘t Hoen, Medicines Law & Policy, at the World Trade Organization-World Health Organization High-Level Dialogue on Expanding COVID-19 Vaccine Manufacturing to Promote Equitable...
Written remarks submitted to the OHCHR following the Expert Workshop on the key challenges...
This blog was submitted by Dr. Katrina Perehudoff, Law Centre for Health and Rights at the University of Amsterdam, and Medicines Law & Policy,...
European Commission Publishes Expert Panel’s Recommendations on High Drug Prices
This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
Wrapping up 2022 with some noteworthy medicines, law and policy events
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy.
Also in 2022, Covid-19 remained a central...
The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...
Thank you for the opportunity to make a brief statement.
The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...